問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Radiation Therapy

Digestive System Department

Kaohsiung Municipal FENG-SHAN Hospital (在職)

Digestive System Department

更新時間：2023-09-19

郭垣宏
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭垣宏

List

44Cases

2026-01-01 - 2029-08-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2025-01-01 - 2029-12-31

Phase II

Active
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    輸注液

Participate Sites
9Sites

Recruiting9Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    V937;吉舒達®/Keytruda®

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2017-11-01 - 2021-05-20

Phase III

Completed
A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    unresectable HCC

  • Test Drug

    Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-10-01 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-01-01 - 2032-03-10

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2010-10-20 - 2012-03-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2019-11-30 - 2026-09-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
9Sites

Recruiting9Sites

2021-03-01 - 2026-12-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2022-01-01 - 2026-03-31

Phase II

Active
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    CVM-1118 膠囊 (又名 CVM-1118 速放膠囊 )

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB